Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | SHR-A1904 |
Synonyms | |
Therapy Description |
SHR-A1904 is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting an undisclosed tumor-associated antigen (TAA) linked to an undisclosed cytotoxic drug, which potentially leads to killing of tumor cells expressing the TAA (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SHR-A1904 | SHRA1904|SHR A1904|SHRA 1940 | SHR-A1904 is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting an undisclosed tumor-associated antigen (TAA) linked to an undisclosed cytotoxic drug, which potentially leads to killing of tumor cells expressing the TAA (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05277168 | Phase Ib/II | SHR-A1904 | A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | Recruiting | USA | AUS | 1 |